Literature DB >> 30867220

Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer.

Nabeela A Khan1, Konrad H Stopsack2,3, Emma H Allott3,4, Travis Gerke3,5, Edward L Giovannucci3,6,7, Lorelei A Mucci3,7, Philip W Kantoff1.   

Abstract

BACKGROUND: Higher intratumoral cholesterol synthesis is associated with a worse prognosis in prostate cancer. The vitamin D-regulated enzyme sterol-27-hydroxylase (CYP27A1) converts cholesterol to 27-hydroxycholesterol, potentially lowering intracellular cholesterol levels. We hypothesized that low CYP27A1 expression is associated with high cholesterol synthesis, low vitamin D signaling, and higher risk of lethal prostate cancer.
METHODS: In 404 patients from the prospective prostate cancer cohorts within the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS), we assessed intratumoral CYP27A1 expression and proxies of cholesterol synthesis using transcriptome profiling, prediagnostic plasma 25-hydroxyvitamin D [25(OH)D; n = 132], and intratumoral vitamin D receptor protein expression (VDR; n = 300). Patients were followed for metastases and prostate cancer mortality (lethal cancer; median follow-up, 15.3 years).
RESULTS: CYP27A1 expression was lower in tumors with higher Gleason grade and higher expression of cholesterol synthesis enzymes, including the second rate-limiting enzyme, SQLE. We did not detect consistent associations between CYP27A1 and 25(OH)D, VDR, or CYP24A1 mRNA expression. Lower CYP27A1 was associated with higher risk of lethal cancer in both cohorts, independent of SQLE [adjusted OR for lowest vs. highest quartile of CYP27A1, 2.64; 95% confidence interval (CI), 1.24-5.62]. This association was attenuated when additionally adjusting for Gleason grade (OR, 1.76; 95% CI, 0.75-4.17).
CONCLUSIONS: Low CYP27A1 expression was associated with higher cholesterol synthesis and a higher risk of lethal disease. IMPACT: These observations further support the hypothesis that intratumoral cholesterol accumulation through higher synthesis and decreased catabolism is a feature of lethal prostate cancer. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 30867220      PMCID: PMC6548616          DOI: 10.1158/1055-9965.EPI-18-1083

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

1.  Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.

Authors:  Erik J Tokar; Mukta M Webber
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.

Authors:  Edward Giovannucci; Yan Liu; Elizabeth A Platz; Meir J Stampfer; Walter C Willett
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

3.  1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Authors:  Michele N Washington; Nancy L Weigel
Journal:  Endocrinology       Date:  2010-02-10       Impact factor: 4.736

4.  Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study.

Authors:  G David Batty; Mika Kivimäki; Robert Clarke; George Davey Smith; Martin J Shipley
Journal:  Cancer Causes Control       Date:  2010-11-30       Impact factor: 2.506

Review 5.  Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials.

Authors:  W G Christen; J M Gaziano; C H Hennekens
Journal:  Ann Epidemiol       Date:  2000-02       Impact factor: 3.797

6.  27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen.

Authors:  Michihisa Umetani; Hideharu Domoto; Andrew K Gormley; Ivan S Yuhanna; Carolyn L Cummins; Norman B Javitt; Kenneth S Korach; Philip W Shaul; David J Mangelsdorf
Journal:  Nat Med       Date:  2007-09-16       Impact factor: 53.440

7.  Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.

Authors:  Elizabeth A Platz; Michael F Leitzmann; Bruce W Hollis; Walter C Willett; Edward Giovannucci
Journal:  Cancer Causes Control       Date:  2004-04       Impact factor: 2.506

8.  Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.

Authors:  Simona Nanni; Valentina Benvenuti; Annalisa Grasselli; Carmen Priolo; Aurora Aiello; Stefania Mattiussi; Claudia Colussi; Vittoria Lirangi; Barbara Illi; Manuela D'Eletto; Anna Maria Cianciulli; Michele Gallucci; Piero De Carli; Steno Sentinelli; Marcella Mottolese; Paolo Carlini; Lidia Strigari; Stephen Finn; Elke Mueller; Giorgio Arcangeli; Carlo Gaetano; Maurizio C Capogrossi; Raffaele Perrone Donnorso; Silvia Bacchetti; Ada Sacchi; Alfredo Pontecorvi; Massimo Loda; Antonella Farsetti
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

9.  Association between plasma cholesterol and prostate cancer in the PSA era.

Authors:  Elizabeth A Platz; Steven K Clinton; Edward Giovannucci
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

10.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.

Authors:  Kenji Tamura; Mutsuo Furihata; Tatsuhiko Tsunoda; Shingo Ashida; Ryo Takata; Wataru Obara; Hiroki Yoshioka; Yataro Daigo; Yasutomo Nasu; Hiromi Kumon; Hiroyuki Konaka; Mikio Namiki; Keiichi Tozawa; Kenjiro Kohri; Nozomu Tanji; Masayoshi Yokoyama; Toru Shimazui; Hideyuki Akaza; Yoichi Mizutani; Tsuneharu Miki; Tomoaki Fujioka; Taro Shuin; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

View more
  6 in total

1.  Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial.

Authors:  Kathleen Torkko; Cathee Till; Catherine M Tangen; Phyllis J Goodman; Xiaoling Song; Jeannette M Schenk; M Scott Lucia; Ulrike Peters; Adrie van Bokhoven; Ian M Thompson; Marian L Neuhouser
Journal:  Cancer Prev Res (Phila)       Date:  2020-02-26

2.  CASC1 Expression in Bladder Cancer Is Regulated by Exosomal miRNA-150: A Comprehensive Pan-Cancer and Bioinformatics Study.

Authors:  Huarong Luo; Chengdang Xu; Bujun Ge; Tianru Wang
Journal:  Comput Math Methods Med       Date:  2022-07-05       Impact factor: 2.809

Review 3.  Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells.

Authors:  Mariarosaria Negri; Annalisa Gentile; Cristina de Angelis; Tatiana Montò; Roberta Patalano; Annamaria Colao; Rosario Pivonello; Claudia Pivonello
Journal:  Nutrients       Date:  2020-06-17       Impact factor: 5.717

4.  Systematic Elucidation of the Aneuploidy Landscape and Identification of Aneuploidy Driver Genes in Prostate Cancer.

Authors:  Yun Peng; Yuxuan Song; Haitao Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-21

5.  Identification of Vitamin D-related gene signature to predict colorectal cancer prognosis.

Authors:  Luping Bu; Fengxing Huang; Mengting Li; Yanan Peng; Haizhou Wang; Meng Zhang; Liqun Peng; Lan Liu; Qiu Zhao
Journal:  PeerJ       Date:  2021-05-13       Impact factor: 2.984

6.  Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma.

Authors:  Venugopal Gunda; Thiago C Genaro-Mattos; Jyoti B Kaushal; Ramakanth Chirravuri-Venkata; Gopalakrishnan Natarajan; Kavita Mallya; Paul M Grandgenett; Karoly Mirnics; Surinder K Batra; Zeljka Korade; Satyanarayana Rachagani
Journal:  Metabolites       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.